Hypothesis

Indole‑3‑propionic acid (IPA) activates the pregnane X receptor (PXR) in intestinal epithelial cells, which in turn attenuates mTORC1 activity to shift cellular resources from proliferation toward barrier‑strengthening programs.

Rationale

• IPA‑PXR signaling upregulates tight‑junction proteins (Occludin, Claudin‑1, Claudin‑4, ZO‑1) and suppresses NF‑κB/TLR4‑driven inflammation【1】.
• mTORC1 integrates nutrient status to control translation, growth, and proliferation; tissue‑specific mTOR modulation shows divergent effects on lifespan and function【2】.
• No study has directly connected PXR activation to mTORC1 regulation in the gut epithelium, despite both pathways governing barrier homeostasis.

We propose that ligand‑bound PXR recruits a corepressor complex that includes DEPTOR or TSC2, leading to reduced Rheb‑GTP loading and diminished mTORC1 signaling. This creates a feedback loop where enhanced barrier integrity reduces microbial translocation, lowering luminal stimuli that would otherwise activate mTORC1 via growth‑factor pathways.

Testable Predictions

1. Pharmacological activation of PXR with IPA (or a selective agonist) in human colonic organoids will decrease phosphorylated S6K (p‑S6K) and 4E‑BP1 levels within 2 h, an effect abolished in PXR‑KO organoids.
2. Genetic loss of PXR in intestinal epithelium (Villin‑Cre;Pxr^fl/fl mice) will result in elevated baseline mTORC1 activity (higher p‑S6K) and increased crypt proliferation (Ki‑67^+ cells) despite unchanged nutrient intake.
3. Rescue experiment: treating PXR‑deficient mice with low‑dose rapamycin will normalize crypt proliferation and partially restore barrier function (measured by FITC‑dextran permeability) to wild‑type levels.
4. Aging correlation: aged mice with depleted Clostridium sporogenes will show reduced luminal IPA, heightened epithelial mTORC1 signaling, and leaky gut; supplementing IPA should reverse both molecular and physiological phenotypes.

Experimental Approach

• Use human colonic organoids treated with 10 µM IPA; collect lysates at 0, 30, 60, 120 min for Western blot of p‑S6K, p‑4EBP1, total S6K, and PXR target genes (CYP3A4, MDR1).
• Perform parallel assays in organoids derived from PXR‑knockout CRISPR lines.
• In vivo, administer IPA (20 mg/kg/day) via drinking water to young and aged mice; assess intestinal mTORC1 activity, barrier permeability, and microbiota composition over 8 weeks.
• Include rapamycin (0.5 mg/kg) as a positive control for mTORC1 inhibition.

Potential Outcomes and Interpretation

• If IPA‑PXR signaling suppresses mTORC1, we will observe a rapid decrease in p‑S6K that correlates with increased expression of tight‑junction genes. Loss of this suppression in PXR‑deficient contexts would manifest as hyperproliferative, leaky epithelium, supporting the idea that the IPA‑PXR‑mTOR axis functions as a resource‑allocation dial prioritizing barrier maintenance over growth when microbial‑derived signals are abundant.
• Failure to detect changes in mTORC1 activity would falsify the hypothesis, suggesting that IPA‑PXR influences barrier function through entirely mTOR‑independent mechanisms.

Broader Impact

Linking a microbial metabolite to the central growth regulator mTOR provides a mechanistic explanation for how diet‑microbiota interactions influence intestinal health during aging. It also reveals a potential therapeutic node where modulating PXR could fine‑tune mTOR‑dependent processes without systemic immunosuppression, addressing the trade‑off between cellular "civilization" (specialized barrier function) and "survival" (proliferative growth) highlighted in longevity research.